Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …

Recompensation has gained increasing attention in the field of cirrhosis, particularly in
chronic liver disease with a definite aetiology. The current global prevalence of obesity and …

Background & Aims Gastrointestinal diseases account for considerable health care use and
expenditures. We estimated the annual burden, costs, and research funding associated with …

Tens of thousands of patients with advanced lung diseases may be eligible to be considered
as potential candidates for lung transplant around the world each year. The timing of referral …

Non-alcoholic fatty liver disease (NAFLD) is projected to become the leading cause of
hepatocellular carcinoma (HCC) in many countries. Many risk factors for NAFLD are also …

In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Nonalcoholic fatty liver disease (NAFLD), affecting about 25% of general population and
more than 50% of dysmetabolic patients, is an emerging cause of chronic liver disease and …

Liver transplantation offers live-saving therapy for patients with complications of cirrhosis
and stage T2 hepatocellular carcinoma. The demand for organs far outstrips the supply, and …

The global burden of viral hepatitis is substantial; in terms of mortality, hepatitis B virus and
hepatitis C virus infections are on a par with HIV, malaria and tuberculosis, among the top …

Background Indications for liver transplantation for hepatocellular carcinoma are evolving
and so-called expanded criteria remain debated. Locoregional therapies are able to …